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OBJECTIVE — Tight glycemic control (TGC) in critically ill patients is associated with an
increased risk of hypoglycemia. Whether those short episodes of hypoglycemia are associated
withadversemorbidityandmortalityisamatterofdiscussion.Usingacase-controlstudydesign,
we investigated whether hypoglycemia under TGC causes permanent neurocognitive dysfunc-
tion in patients surviving critical illness.
RESEARCH DESIGN AND METHODS — From our patient data management system,
we identiﬁed adult survivors treated for 72 h in our surgical intensive care unit (ICU) between
2004 and 2007 (n  4,635) without a history of neurocognitive dysfunction or structural brain
abnormalities who experienced at least one episode of hypoglycemia during treatment (hypo
group)(n37).Foreachhypogrouppatient,onepatientstringentlymatchedfordemographic-
and disease-related data were identiﬁed as a control subject. We performed a battery of neuro-
psychological tests investigating ﬁve areas of cognitive functioning in both groups at least 1 year
after ICU discharge. Test results were compared with data from healthy control subjects and
between groups.
RESULTS — Critical illness caused neurocognitive dysfunction in all tested domains in both
groups. The dysfunction was aggravated in hypo group patients in one domain, namely that of
visuospatial skills (P  0.01). Besides hypoglycemia, both hyperglycemia (r  0.322; P 
0.005) and ﬂuctuations of blood glucose (r  0.309; P  0.008) were associated with worse
test results in this domain.
CONCLUSIONS — Hypoglycemia was found to aggravate critical illness–induced neuro-
cognitive dysfunction to a limited, but signiﬁcant, extent; however, an impact of hyperglycemia
and ﬂuctuations of blood glucose on neurocognitive function cannot be excluded.
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S
ince the concept of tight glycemic
control (TGC) was introduced in
criticalcaremedicinein2001(1),its
implementation in daily clinical practice
has been the subject of a vivid discussion.
Several single-center trials in different pa-
tient populations largely conﬁrmed the
clinical beneﬁts, at least when patients
were treated for a few days or longer in an
intensive care unit (ICU) (2). Numerous
studies have suggested plausible mecha-
nisms behind the clinical beneﬁts (3).
However, a recent multicenter trial failed
to conﬁrm the strict blood glucose targets
(4), and two multicenter trials have been
preliminarily stopped because of a high
incidence of hypoglycemic episodes (5).
Indeed, hypoglycemia appears as the
major side effect of any effort to regulate
blood glucose levels with insulin, what-
ever the blood glucose levels aimed for
(2). Although numerous algorithms are
availabletominimizethisrisk(6),thefear
of hypoglycemia-induced mortality and
permanent disability largely impedes the
implementation of TGC in daily routine.
Scientiﬁc evidence supporting the com-
mon notion that hypoglycemia is respon-
sible for an increased mortality and
profound permanent neurocognitive dys-
functionratherthanitbeingjustamarker
of severity of illness is poor and contro-
versial, however. Efforts to substantiate
any evidence are based on post hoc anal-
yses, since conﬁrmation from prospective
randomized, controlled trials is pre-
cluded for obvious ethical reasons. Some
studies imply that any mortality beneﬁts
of TGC might be outweighed when the
incidence of hypoglycemia is very high
(7); however, other analyses revealed
conﬂicting results in this respect (8). Be-
sidesdirecteffectsonmortality,neurogly-
copenia might cause neuronal damage
and at least subtle permanent neurocog-
nitive impairment that potentially affects
lifequalityafterdischarge.Fromdiabetes,
it is known that neuroglycopenia might
have a permanent effect on neurocogni-
tive function, at least when it occurs re-
petitively. Since diabetes and critical
illness–induced dysregulations of glucose
homeostasis represent substantially
different entities, it is inappropriate to
extrapolate these data to the ICU popula-
tion. Cognitive impairment is a relevant
problem of patients surviving critical ill-
nessingeneral(9).Currently,thereareno
data available on the speciﬁc impact of
hypoglycemic events during treatment in
ICU on long-term neurocognitive func-
tion. Using a case-control design, we
investigated whether hypoglycemic epi-
sodes under TGC induce or aggravate
permanent neurocognitive deﬁcits in pa-
tients surviving critical illness.
RESEARCH DESIGN AND
METHODS — The work was approved
bythelocalethicscommittee,andwritten
informed consent was obtained from all
patients prior to neurocognitive testing.
All patients in the surgical ICU of our
university hospital are treated according
to our institutional TGC protocol (analog
to [1]), aiming for blood glucose between
80 and 110 mg/dl using insulin infusions
asnecessary.Bloodglucosewasmeasured
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with an ABL blood gas analyzer (glucose
oxidase method with amperometric read-
ing, range 7–540 mg/dl, coefﬁcient of
variance 10% for lower detection limit;
Radiometer, Copenhagen, Denmark).
Quality checks of the device were per-
formed according to the instruction
manual.
We identiﬁed all patients who suf-
fered from at least one episode of hypo-
glycemia (blood glucose 40 mg/dl)
(labeled the hypo group) between 1 Jan-
uary 2004 and 31 December 2007 from
our patient data management system. Pa-
tients were selected to undergo a battery
of validated neuropsychological tests that
weredesignedtoassessafullrangeofcog-
nitive functions (Table 1) at least 1 year
afterdischargefromtheunit.Todiagnose
patients with manifest neurological deﬁ-
cits,ashortneurologicalexaminationwas
performed(sensoryandmotorresponses,
reﬂexesincludingBabinski’ssign,andex-
amination of posture and movements).
We included all patients, aged between
18 and 80 years, upon admission who
were treated for at least 72 h in the ICU.
Weexcludedpatientswhodidnotsurvive
until the scheduled time point of testing
or had a medical history or medical con-
dition potentially biasing neuro-
cognitive testing, such as neurocognitive,
neurodegenerative (Alzheimer’s or Par-
kinson’s disease), psychiatric disorders
(drug abuse, depression, and schizophre-
nia and the use of respective medication),
severe liver disease (ammonia three times
the upper limit of normal or Child C liver
insufﬁciency), or end-stage kidney fail-
ure. Patients after neurotrauma, intracra-
nial hemorrhage, stroke, intracranial
surgery,andotherstructuralbrainlesions
were also excluded.
For each hypo group patient, a
matchingpartner(controlgroup)without
any hypoglycemic event meeting the
same inclusion and exclusion criteria was
identiﬁed from the database according to
strict demographic- and illness-related
matching criteria (Table 2).
We recorded and calculated duration
(time from last blood glucose above hy-
poglycemia threshold before, to ﬁrst
Table 1—Cognitive domains and tests: results of neurocognitive testing
Hypo group Control group
Score
(percentile) Evaluation Z scores
Score
(percentile) Evaluation Z scores P
Dementia screening 0.006 0.003 0.969
Mini-mental state examination 28.4 Close below average 28.8 Close below average 0.909
Boston Naming Test 13.8 Normal 13.9 Normal 0.871
Attention and working memory 0.039 0.045 0.774
Nuernberg Gerontopsychological
Inventory
Digit symbol substitution 30.0 (56.7) Normal 31.1 (60.7) Normal 0.770
Color word interference task
(reading) 39.8 (10.2) Far below average 40.0 (12.5) Far below average 0.861
Color word interference task
(color naming) 53.3 (28.4) Close below average 52.8 (26.6) Close below average 0.608
Wechsler Memory Scale (revised)
Digit span forward 11.6 (51.7) Normal 12.6 (54.4) Normal 0.156
Digit span backward 10.7 (40.6) Close below average 11.6 (42.0) Close below average 0.892
Trail-making test (A) 60.1 (13.9) Far below average 59.6 (13.0) Far below average 0.270
Executive function 0.001 0.007 0.991
Color word interference task
(interference condition) 17.5 (47.9) Normal 19.5 (51.3) Normal 0.421
Regensburg Word Fluency Test
(letter ﬂuency) (S) 14.2 (28.4) Close below average 14.2 (28.4) Close below average 1.000
Trail-making test (B) 117.0 (27.8) Close below average 110.8 (25.6) Close below average 0.792
Visuospatial skills 2.084 0.145 0.001
Rey Osterrieth Complex Figure
Test
Copy 20.4 24.7 0.007
Delayed recall 9.4 (22.8) Close below average 14.5 (29.9) Close below average 0.002
Difference copy (delayed) 54.3% 41.9% (4.2) 0.043
Verbal learning and memory 0.027 0.064 0.807
Auditory verbal learning test
(German)
Recall trial 1 4.9 (30.2) Close below average 5.5 (38.4) Close below average 0.503
Recall trial 5 10.7 (31.1) Close below average 10.5 (28.8) Close below average 0.543
Total trials 1–5 38.0 (30.4) Close below average 38.7 (32.1) Close below average 0.527
Delayed recall 8.5 (13.8) Far below average 9.0 (15.0) Far below average 0.240
Recognition (true positives, false
positives) 10.9 (30.5) Close below average 10.9 (30.5) Close below average 1.000
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cemic reading), number and severity of
hypoglycemia (minimum blood glucose
during treatment), mean blood glucose
over the whole ICU stay, mean morning
blood glucose, maximum blood glucose,
blood glucose (difference between the
minimum blood glucose and maximum
blood glucose within 6 h following hypo-
glycemia), and the difference between
minimum and maximum blood glucose
during ICU treatment.
Neuropsychological assessment
Oneinvestigator,whowasunawareofthe
allocation of the patients, conducted the
neuropsychological tests. Test results
were primarily analyzed by the same in-
vestigator and supervised by an experi-
enced clinical neuropsychologist.
Performances in ﬁve major areas of cog-
nitive functioning were evaluated. Cogni-
tive domains and their particular tests are
listed in Table 1. Concerning the Rey
Osterrieth Complex Figure Test, we also
calculated the relative difference between
both test results since results of delayed
recall performance can be inﬂuenced by
an impairment of initial copying. Addi-
tionally, test results from patients were
compared with published normative data
for age, sex, and educational level. A de-
tailed description of each test can be
found in the book by Lezak (10).
Statistical analyses
Data were tested for normal distribution
withtheShapiro-WilkTest.Todetermine
meaningful composite scores of cognitive
domains, we performed a principal com-
ponent analysis using the single test re-
sults, followed by an oblique (Oblimin
with Kaiser normalization) rotation. The
same test was not included in more than
one composite score. The resulting ﬁve
factors of the principal component analy-
sis were Z transformed (mean score of 0
and an SD of 1). For timed tests, the sign
of the Z score was reversed so that im-
proved performance resulted in a higher
score in all tests.
Primary analysis assessed differences
in neurocognitive test results between
groups with either paired t test or Mann-
Whitney U test as appropriate. Secondary
analyses were carried out to test the rela-
tion of hypoglycemia severity, length of
hypoglycemicepisode,andthenumberof
hypoglycemic events to neurocognitive
scores and whether maximum glucose
values, blood glucose, or the difference
between minimum and maximum blood
glucose were associated with worse test
results by means of Pearson’s correlation.
Test results of the ICU patients were
compared with published normative data
for age, sex, and educational level. Differ-
ences were expressed semi-quantitatively
as normal, close below average, or far be-
low average, respectively. Test results are
givenasmeansSD.Atwo-tailedPvalue
0.05 was considered signiﬁcant. All
data were analyzed using SPSS Statistics
version 15.0.
RESULTS— A total of 4,635 patients
were treated in our ICU in the study pe-
riodfor72h,193ofwhomexperienced
at least one episode of hypoglycemia
(4.2%).Thirty-sevenhypogrouppatients
met inclusion criteria, fulﬁlled no exclu-
sion criteria, and one matching control
partner could be identiﬁed for each (Fig.
1). Demographic data were as follows
(means  SE): 44 male and 30 female
subjects, age 66.3  1.3 years, simpliﬁed
acutephysiologyscore392.3,lengthof
stay on ICU 15.2  1.6 days, and 32%
had diabetes. Admission blood glucose
(167.8 7.8vs.167.0 8.3 mg/dl;P
Table 2—Matching criteria
Demography
Sex Male/female
Age (classiﬁed in groups) 40; 41–60; 61–75; 75 years
Simpliﬁed acute physiology score
(maximum simpliﬁed acute physiology
score, classiﬁed in groups)
7; 8–14; 14
Year of ICU treatment
Disease-related criteria
Type of surgery Elective surgery/emergency surgery
Cardiopulmonary resuscitation Yes/no
Type 1 or type 2 diabetes Yes/no
Length of stay in ICU*
Mean morning blood glucose*
Duration of sedation (classiﬁed in groups) 3 days; 3–7 days; 1–2 weeks; 2 weeks
Respiratory failure (classiﬁed by Horrowitz
Index in groups)† 300; 200–300; 200
Cardiovascular failure† Catecholamine therapy: yes/no; mechanical
assist device: yes/no
Renal failure† Hemodialysis of any kind: yes/no; classiﬁed
by RIFLE criteria
Hepatic failure (classiﬁed by laboratory liver
testing, classiﬁed in four groups) All values 2.5 ULN, one value 2.5–5 ULN,
one value 5 ULN, all values 5 ULN
Medication Steroids: yes/no; immunosuppressants:
yes/no
*Smallest possible difference. †At time of hypoglycemia 3 days. ULN, upper limit of normal. RIFLE, Risk,
Injury, Failure, Loss, and End-stage classiﬁcation for acute renal dysfunction.
Figure 1—Flow chart of patient inclusion in
the hypo group.
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(131.7  3.0 vs. 126.5  2.6
mg/dl; P  0.196), and mean blood glu-
cose (139.0  3.0 vs. 137.1  2.5; P 
0.644) did not differ between groups.
Meanmaximumbloodglucosewassignif-
icantly higher in the hypo group than in
the control group (297.8  14.9 vs.
249.8  10.7 mg/dl; P  0.017). Demo-
graphic data did not differ between
groups, as patients were matched
accordingly.
None of the patients revealed mani-
fest neurological deﬁcits in the neurolog-
ical examination. Neurocognitive tests in
both patient groups showed impaired
neurocognitive function in several do-
mains compared with age-matched
healthy control subjects (Table 1). Analy-
ses of differences between both patient
groups in the ﬁve neurocognitive do-
mains revealed solely a signiﬁcant im-
pairment of visuospatial skills in the
hypo compared with the control group
(P  0.001). Within the single subtests,
results of both copy (P  0.007) and
delayed (P  0.002) recall of the Rey
Osterrieth Complex Figure Test were
lower in the hypo than in the control
group. The relative difference between
copy and delayed recall also signiﬁ-
cantly differed between both groups
(hypo group  control group; P 
0.043). Results of all other tests did not
differ between groups (Table 1).
Solely within the hypoglycemic group,
the maximum blood glucose and the dif-
ference between minimum and maxi-
mum blood glucose serving as rough
surrogatesforthequalityofglycemiccon-
trolduringICUtreatmentwerenegatively
correlated with visual-spatial processing
parameters. Neither the number nor the
duration of hypoglycemic episodes
showed a signiﬁcant correlation. Severity
ofhypoglycemiawasalsonotsigniﬁcantly
associated with visuospatial performance
but did show a negative trend (Table 3).
In the control group, no correlations be-
tweenparametersofglycemiccontroland
the performance in the neurocognitive
tests were found.
CONCLUSIONS — In the current
case-controlstudy,wefoundthatpatients
who experienced one or more hypoglyce-
mic events during ICU treatment showed
an aggravation of critical illness–induced
neurocognitive dysfunction compared
with patients who did not experience hy-
poglycemia. Both groups showed signiﬁ-
cant neurocognitive dysfunctions in all
domains compared with healthy control
subjects, but hypo group patients had an
additional deﬁcit in visuospatial skills.
Since tests were done at least 1 year after
ICU discharge, these impairments must
beconsideredlongtermifnotpermanent.
Former studies investigating the con-
sequencesofhypoglycemiaunderTGCin
the critically ill have revealed conﬂicting
results (7,8); however, they have been
primarily focused on mortality and gross
somatic morbidity. Data on the positive
effectsofTGConmortalityfrompriortri-
als could not be conﬁrmed by the recent
multicenter trial Normoglycaemia in In-
tensive Care Evaluation–Survival Using
Glucose Algorithm Regulation (NICE-
SUGAR) (4), which investigated the im-
pact of a strict versus a more liberal TGC
protocol. NICE-SUGAR revealed a higher
mortality in the strict TGC group. The
high incidence of hypoglycemia in the
strictTGCgroupmightbeconsideredone
possible explanation for this controversy.
Similarly, from mathematical modeling,
Krinsley concluded that negative effects
of hypoglycemia might outweigh any
beneﬁts on mortality and gross morbidity
when they occur in a critical incidence
(7). Our study focuses on ICU survivors
and is thus the ﬁrst to explore the long-
term effects of hypoglycemia under TGC
during ICU treatment on subtle neuro-
psychological function. With the utilized
test battery, we largely conﬁrm and com-
plement prior studies (9) demonstrating
neurocognitive impairment in the tested
domains in both critically ill patient
groups compared with age-, sex-, and ed-
ucational level–matched healthy control
subjects. Furthermore, we could show
thatinpatientssurvivingtheICUwithout
primary brain damage and preexisting
neurocognitive deﬁcits, critical illness–
induced deﬁcits of complex neurocognitive
functions, in particular visuoconstructive
performance as well as ﬁgural and spatial
aspects of nonverbal memory, might be ag-
gravated by even a single episode of hypo-
glycemia.Althoughtheaggravationappears
minor at ﬁrst view and is restricted to one
single domain, the impairment of visual-
spatialprocessingmighthavearelevantim-
pact on overall daily functioning (11). It
could be associated with the evolution of
further cognitive decline over time (12)
and, thus, have a signiﬁcant impact on pa-
tients’ quality of life.
Recent studies have indicated that an
impairment of visuoconstructive skills
and both ﬁgural and spatial aspects of
nonverbal memory are associated with
temporal and hippocampal dysfunction
(13). Neuroimaging has demonstrated
that not all neurons and brain regions are
equally sensitive to hypoglycemic injury
but that there appears to be a selective
vulnerability of especially those hip-
pocampal and/or temporal neurons, fol-
lowed by neurons in the basal ganglia
(14,15). Although the reported abnor-
malities could be transient and reversible
by glucose infusion, several studies in
both animals and humans have consis-
tently demonstrated hypoglycemia-
induced permanent neuronal damage in
regions of the hippocampus, especially in
the dentate gyrus (16,17). Although most
biochemical studies have focused on cell
death, more recent studies indicate that
mild, recurrent hypoglycemia can cause
synaptic dysfunction even in the absence
of neuronal death, particularly in hip-
pocampal neurons (18). Repeated epi-
sodes of even moderate hypoglycemia in
diabetic patients have been reported as
being associated with a decline of intelli-
gence quotient, persistent cognitive im-
pairment, and other long-term effects
such as mood changes and affected gen-
eral well-being (19,20); however, since
conﬂicting results have been published,
assigning hypoglycemia as the sole cause
oftheseﬁndingsisdebatable.Someofthe
divergent results may be due to method-
ical issues with regards to the determina-
tion of cognitive function; other negative
studies may not have been sufﬁciently
long to detect a signiﬁcant effect. On the
other hand, the associations between in-
tellectual disadvantage and episodes of
Table 3—Correlation of the parameters of
glycemic control with Rey Osterrieth Com-
plex Figure Test results in the hypo group
rP
Mean morning blood
glucose 0.055 0.747
Mean blood glucose 0.116 0.494
Number of hypoglycemic
episodes 0.097 0.414
Duration of hypoglycemic
episode 0.293 0.154
Maximum blood glucose
during treatment 0.322 0.005
Minimum blood glucose
during treatment 0.299 0.072
Difference maximum/
minimum blood
glucose 0.309 0.001
Blood glucose 0.052 0.765
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patients manage their insulin treatment
lessaccurately.Itisthusdifﬁculttodiffer-
entiate between effects of hypoglycemia
and modest glycemic control comprising
hyperglycemia, hypoglycemia, and blood
glucose ﬂuctuations. To conclude from
clinical trials that persistent neurocogni-
tive impairment in diabetic subjects is ex-
clusively a consequence of (repeated)
episodes of hypoglycemia is plausible but
not imperative. Moreover, the underlying
pathogenetic mechanisms of the long-
term cognitive deﬁcits remain largely
unclear; some ﬁndings indicate that do-
paminergic functional disturbance in the
hippocampus (21) and changes in brain
glucose transporters or astrocyte-neuron
interactions may play a major role (14).
The agreement between neurocognitive
test results, their probable functional and
structural neuroanatomic correlates, and
the speciﬁc vulnerability of (para-) hip-
pocampal neuron populations to hypo-
glycemic damage is striking, however.
Current data suggest that a great por-
tion of ICU survivors in general develop
persistent cognitive impairment (9,22);
wealsofoundneurocognitiveimpairment
in various domains in both our patient
groups compared with published norma-
tive data. Since critically ill patients, per
se, seem to be at risk for neural damage,
one might speculate that critical illness
can induce a speciﬁc vulnerability of neu-
rons to glucose deprivation. Our data
show that hypoglycemic events under
TGC aggravate these critical illness–
induced neurocognitive deﬁcits but that
this is limited to one neurocognitive do-
main. Notwithstanding stringent match-
ing criteria for demographic and severity
of illness data including mean blood glu-
cose, we cannot completely exclude con-
founders. Our groups differ in mean
maximum and minimum glucose, sug-
gestingthatthehypogroupexperienceda
worse quality of blood glucose control
with more variability. Solely within the
hypo group, we found a signiﬁcant asso-
ciation of hyperglycemia and the differ-
ence between lowest and highest blood
glucose with declined visuospatial skills,
whereas for quantity and duration of hy-
poglycemic episodes, no such correlation
was found. No correlations at all were
found in our control group. Indeed, pre-
viousworkshowedthathyperglycemiain
diabetes, too, is associated with adverse
effects on the brain (23), neurocognitive
impairment, and affected general well-
being (19). Not only hypoglycemia but
also hyperglycemia, glucose ﬂuctuations,
and their treatments thus might have an
impact on cognitive function of ICU
survivors. Moreover, neural death is ag-
gravated when glucose concentrations
rise rapidly and hyperglycemia occurs af-
ter hypoglycemia (“glucose reperfusion
injury” [24]). Notably, critically ill pa-
tients reveal increased insulin levels, and
insulin has also been reported to acceler-
ate neural cell death in the hippocampus
during low glucose levels, suggesting that
insulin might have a double-edged effect
on neuron death dependent on glucose
concentration (25). Our ﬁndings are in
accordance with these data. Since exclu-
sively in the hypo group a correlation of
hyperglycemia and a surrogate parameter
of the quality of glycemic control with
neurocognitive dysfunction was found,
we cannot rule out those parameters as
relevant confounders of our ﬁndings.
However, our hypothesis and design only
allow to draw a causal link between hy-
poglycemia and neurocognitive impair-
ment. It is undue to conclude causality
between maximum blood glucose or glu-
cose ﬂuctuations from our data; we solely
can allude to an association.
To unequivocally prove a causal rela-
tion between hypoglycemia and neuro-
cognitive dysfunction, a prospective,
randomized controlled trial would be re-
quired, but self-evident, ethical consider-
ations preclude this approach. We thus
have to rely on the available data from
post hoc analysis with its limitations. An-
other limitation is the absence of brain
imaging in all patients. Signiﬁcant struc-
tural brain lesions are unlikely, however,
since none of the patients revealed mani-
fest neurological deﬁcits during the
study period. However, subtle struc-
tural cerebral lesions cannot completely
be excluded.
In conclusion, neurocognitive dys-
function is common in patients surviv-
ing critical illness. Patients who
experienced a hypoglycemic event dur-
ingICUtreatmentshowasigniﬁcantad-
ditional impairment in the visuospatial
domain compared with patients who
did not. In those patients, hyperglyce-
mia and ﬂuctuations of blood glucose
levels were also associated with long-
term visuospatial dysfunction and
might thus confound this conclusion.
Every effort should be put in imple-
menting effective blood glucose control
algorithms, largely avoiding hypoglyce-
mia and hyperglycemia as well as large
ﬂuctuations of blood glucose.
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